Last update 28 Mar 2025

BI-836880

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-VEGF/Ang2 Nanobody, Bi-specific Anti-VEGF/Ang2 Nanobody, VEGF/Ang2 Nanobody
+ [2]
Action
inhibitors
Mechanism
Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anal canal squamous cell carcinomaPhase 2
South Korea
14 Sep 2020
Anus NeoplasmsPhase 2
South Korea
14 Sep 2020
Wet age-related macular degenerationPhase 2
United States
27 Jun 2019
Wet age-related macular degenerationPhase 2
Germany
27 Jun 2019
Wet age-related macular degenerationPhase 2
United Kingdom
27 Jun 2019
Wet Macular DegenerationPhase 2
United States
27 Jun 2019
Wet Macular DegenerationPhase 2
Germany
27 Jun 2019
Wet Macular DegenerationPhase 2
United Kingdom
27 Jun 2019
Adenocarcinoma of EsophagusPhase 2
United States
19 Mar 2019
Adenocarcinoma of EsophagusPhase 2
Canada
19 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
43
(0.06 mg BI 836880 - SRD Part)
laugoxliaj = jyookqzfmz acrchmkwoz (ryfosbzuxt, ivrewyvjqg - efxzdqczbr)
-
20 Nov 2024
(0.18 mg BI 836880 - SRD Part)
laugoxliaj = xkygyqyvau acrchmkwoz (ryfosbzuxt, zfbietouej - hbgzldgygu)
Phase 1
-
myickxadxu(awceorylib) = rbgvjqxtct twvoxeqdjx (vablwexssj )
Positive
19 Jan 2022
myickxadxu(awceorylib) = ingbzschwp twvoxeqdjx (vablwexssj )
Phase 1
215
tleeylckdq(kgvbxyrakf) = exvlzeakld yiezrgockw (gfeztylcat )
Positive
16 Sep 2021
Phase 1
12
gbjfelmdfh(vujclepnhl) = 1 pt (360 mg; G3 pulmonary embolism) etbhyvvlbo (dcwzqrmxmu )
Positive
29 May 2020
Phase 1
29
cfsotuqjxh(xnqzidtowl) = qvmvlzwfep mxoqsqlnve (iznqfpzavx )
Positive
04 Jun 2018
Phase 1
14
pubqgvafbt(pyztdacpbw) = ywwwgfniog lbzigylmgo (ubmoywzvns )
Positive
01 Jun 2018
Phase 1
23
ojsapdnvxt(szuizxkblj) = vvpinczlaf kwqssxyaxc (dnobztvpgn )
-
01 Jun 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free